James P. Linton, Ph.D., MBA – Chief Executive Officer (CEO) and President
Dr. Linton has over 25 years of entrepreneur and executive experience in the biotechnology space, co-founding 5 previous companies as well as leading the fund raising and business development efforts in several companies. He has successfully raised over $350M in capital, negotiated over $400M in deals, and has had multiple exits including Protometrix, Genicon, Axiom and Owl Biomedical. Early in his career, Dr. Linton was a post-doctoral fellow at Merck Research Laboratories working on molecular cloning of genes responsible for FK-506-induced immunosuppression. He obtained his M.B.A from the University of California at Davis and his Ph.D. in Molecular Genetics from Emory University.
Paul Predki, Ph.D. – Chief Technology Officer and Head of Research
Dr. Paul Predki served as Vice President for Molecular & Protein Biology R&D at Life Technologies where he joined as part of the acquisition of Protometrix in 2004, a protein microarray company he helped start in 2001 as a spin-out from Yale University. Prior to that he served as Associate Director at the DOE Joint Genome Institute, where he was responsible for the development and implementation of the Institute’s high-throughput production sequencing and genomics programs. Dr. Predki also spent four years at CuraGen Corporation. Dr. Predki did his post-doctoral training at Yale University, where he investigated protein engineering and protein biochemistry. He obtained his Ph.D. in Biochemistry from the University of Toronto. Dr. Predki has published in a variety of high-profile journals, including Science, Nature and Cell.
Stephanie George, PMP – Director of Program Management
Ms. George brings over 25 years of FORTUNE 150 company expertise and is a certified PMI Project Management Professional. During her career, she has carried financial management and project responsibilities for budgets that were cumulatively in excess of $40M. Ms. George served most recently as IT Director at Novartis where she was responsible for managing a variety of high profile projects along with building an IT Software Quality team. Prior to that, Ms. George served for 17 years in IT management at Abbott Laboratories where she was responsible for management of IT enterprise system implementations and software development for Manufacturing, Sales Data Warehouse, Quality and Enterprise Integration applications for the Abbott Vascular division. Her leadership helped build the Abbott’s IT enterprise systems to meet business needs while seamlessly integrating with business processes in additional to ensuring FDA regulatory compliance. Ms. George holds numerous IT & PM certifications and obtained her B.S. degrees from San Diego State University.
Stefen A. Boehme, PhD – Director of Molecular Technologies
Dr. Stefen Boehme has over 20 years of experience in the biotech and biopharma industry and has been involved in the development of multiple therapeutics for inflammatory and allergic diseases. Most recently at Axikin Pharmaceuticals, he used his expertise in molecular biology, protein engineering and enzymology to successfully advance several early stage programs through Phase I & II clinical trials. Dr. Boehme did his post-doctoral training at the National Institutes of Health, and his Ph.D. in Molecular Immunology at the University of Florida. Dr. Boehme has authored 38 research publications and one patent.